Biotechnology investments are accelerating DNA manufacturing across the Asia-Pacific region, according to Healthcare Asia Magazine.
The global DNA manufacturing market is projected to reach $21.82 billion by 2034, growing at a compound annual growth rate (CAGR) of 14.62%, based on estimates from Polaris Market Research cited by Healthcare Asia Magazine.
Growth in the Asia-Pacific region is being driven by increasing biotechnology investments in China, Japan, South Korea, and India, where governments and private sectors are expanding capabilities in genetic engineering, synthetic biology, and advanced therapeutics.
Meanwhile, North America accounted for 47.38% of global revenue in 2024, with the United States leading the region due to strong research funding and regulatory support for genetic technologies. Europe also remains active in the market, supported by pharmaceutical research initiatives and programs such as Horizon Europe.
Demand for DNA manufacturing is largely fueled by expanding investments in gene and cell therapies, particularly for oncology and regenerative medicine. Synthetic DNA currently holds the largest market share because of its broad use in research and synthetic biology platforms.
Market growth is also influenced by the need for Good Manufacturing Practice (GMP)-grade DNA for clinical applications. At the same time, artificial intelligence tools are increasingly used to optimize gene construct design and streamline DNA synthesis timelines.
In 2024, the cell and gene therapy segment generated the largest share of revenue, with key end users including pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations (CROs). CROs play an important role by providing manufacturing services and specialized expertise that help accelerate the development and commercialization of DNA-based products.